Literature DB >> 2519862

Toxicity of intraperitoneally administered antitumour drugs in athymic rats.

C J Lindén1.   

Abstract

The toxicity of eight anticancer drugs given intraperitoneally to athymic rats was investigated to define the maximum tolerable doses (MTD). Drugs were given once weekly. Toxicity was assessed as percentage loss of body weight (LBW%) or percentage toxic death rate (TDR%) during the first week after drug administration. LBW% and TDR% were significantly correlated, r = 0.58 p less than 0.00001. From the regression equation for the relationship between LBW% and TDR%, 10 percent TDR (LD10), usually regarded as equivalent to MTD in animals, was found to correspond to 14 percent LBW. From the individual regression equations for LBW% and dose for each of six drugs, MTDs were calculated to be as follows; doxorubicin 7 mg/kg, cyclophosphamide 100 mg/kg, mitomycin C 1.8 mg/kg, cisplatin 8 mg/kg, vindesine 0.8 mg/kg and vincristine 0.9 mg/kg. LD10 was found to be 40 mg/kg for both carmustine (BCNU) and etoposide.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2519862

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  3 in total

1.  In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy.

Authors:  D Shabat; H N Lode; U Pertl; R A Reisfeld; C Rader; R A Lerner; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-12       Impact factor: 11.205

2.  Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.

Authors:  Tooba A Cheema; Ryuichi Kanai; Geon Woo Kim; Hiroaki Wakimoto; Brent Passer; Samuel D Rabkin; Robert L Martuza
Journal:  Clin Cancer Res       Date:  2011-10-05       Impact factor: 12.531

3.  Oligo-Fucoidan prevents IL-6 and CCL2 production and cooperates with p53 to suppress ATM signaling and tumor progression.

Authors:  Li-Mei Chen; Po-Yen Liu; Yen-An Chen; Hong-Yu Tseng; Pei-Chun Shen; Pai-An Hwang; Hsin-Ling Hsu
Journal:  Sci Rep       Date:  2017-09-19       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.